A PHASE III, RANDOMISED, OPEN-LABEL, BLINDED ENDPOINT, COMPARATIVE TRIAL OF
FERRIC DERISOMALTOSE VERSUS NO INTRAVENOUS IRON IN IRON-DEFICIENT SUBJECTS WITH
SYMPTOMATIC CHRONIC HEART FAILURE
- Registry ID
- P-MONOFER-CHF-02
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- PHARMACOSMOS A/S
- Start date
- 2025-10-06
- Last update
- 2025-02-12
Conditions
- CHRONIC HEART FAILURE
- IRON DEFICIENCY
Related clinical trials
- EASI-HF REDUCED - A PHASE III DOUBLE-BLIND, RANDOMISED, PARALLEL-GROUP
SUPERIORITY TRIAL TO EVALUATE EFFICACY AND SAFETY OF THE COMBINED USE OF ORAL
VICADROSTAT (BI 690517) AND EMPAGLIFLOZIN COMPARED WITH PLACEBO AND
EMPAGLIFLOZIN IN PARTICIPANTS WITH SYMPTOMATIC CHRONIC HEART FAILURE (HF: NYHA
II-IV) AND LEFT VENTRICULAR EJECTION FRACTION (LVEF) < 40%
- A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE
SAFETY AND EFFICACY OF JK07 IN ADULTS WITH CHRONIC HEART FAILURE (RENEU-HF)
- A PHASE III, RANDOMISED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFECT OF BALCINRENONE/DAPAGLIFLOZIN, COMPARED WITH DAPAGLIFLOZIN, ON THE RISK OF HEART FAILURE EVENTS AND CARDIOVASCULAR DEATH IN PATIENTS WITH HEART FAILURE AND IMPAIRED KIDNEY FUNCTION
- POST-OPERATIVE INTRAVENOUS IRON TO TREAT IRON-DEFICIENCY ANEMIA IN PATIENTS UNDERGOING CARDIAC SURGERY: A PILOT, MULTICENTRE, PLACEBO-CONTROLLED RANDOMIZED TRIAL (POAM)
- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3540378 IN ADULTS WITH WORSENING CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)
- FEASIBILITY AND EFFICACY OF INTRAVENOUS FERRIC DERISOMALTOSE TO CORRECT PRE-OPERATIVE IRON-DEFICIENCY ANEMIA IN PATIENTS UNDERGOING GYNECOLOGIC ONCOLOGY SURGERY: A PILOT RANDOMIZED DOUBLE BLINDED PARALLEL GROUP PLACEBO-CONTROLLED STUDY
View on source registry